The study by Zhang et al suggested that CERS6-AS1 was significantly overexpressed in hepatocellular carcinoma, and patients with CERS6-AS1 upregulation exhibited a poor prognosis [9]. This evidence concerns the gene CERS6 and hepatocellular carcinoma.